ArticleFrontiers in medicine2025
Mechanistic insights into the therapeutic effects on liver fibrosis in Wilson's disease: a transcriptomic and network pharmacology-based approach.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The mechanism of the Bushen Huoxue Huazhuo Formula (BSHXHZF) in treating Wilson's disease (WD) liver fibrosis was investigated in this study using transcriptomics, network pharmacology, and molecular docking approaches. Methods: Differentially expressed long non-coding RNAs (DELncRNAs) and messenger RNAs in the liver tissues of different groups were identified using high-throughput chip sequencing. Furthermore, the target genes of DELncRNAs were identified, followed by GO functional enrichment and KEGG pathway analyses. DELncRNAs were validated using quantitative reverse transcription-polymerase chain reaction. Active compounds of BSHXHZF and their associated pathways relevant to liver fibrosis treatment in WD, with initial validation via molecular docking. Results: Transcriptomic analysis identified 63 DELncRNAs by comparing the control with the model and treatment groups. Key DELncRNAs included NONMMUT060008.2, NONMMUT096375.1, and ENSMUST00000153523. Target genes such as Conclusion: The therapeutic effects of BSHXHZF in liver fibrosis associated with WD are likely linked to its modulation of sphingolipid and IL-17 signaling pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.